Lexeo Therapeutics, Inc. LXEO
At closeNov 3, 2026, 4:01 PM EST
After hours · Nov 3, 4:01 PM ET
- YTD
- -68.68%
- 1 year
- -65.60%
- Market cap
- 255.29M
- EPS (ttm)
- -1.02
- Shares out
- 33.08M
- Forward P/E
- -2.24
- YTD return
- -68.68%
- 1-year return
- -65.60%
- Volume
- 1.31M
- Avg volume
- 1.31M
- Open
- 3.10
- Previous close
- 3.06
- Day's range
- 3.01 – 3.30
- 52-week range
- 2.55 – 10.99
- Price target
- 22.29 (+616.6%)
- Earnings date
- May 9, 2024
2Y -5.13 (-62.26%)
Key statistics
- Enterprise value
- 90.11M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 1.46
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -36.83M
- Total cash
- 174.98M
- Total debt
- 10.85M
- Return on equity
- -74.83%
- Short % of float
- 7.42%
- 50-day average
- 7.92
- 200-day average
- 11.86
Analyst view
- Target (low)
- 16.00
- Target (mean)
- 22.29
- Target (high)
- 28.00
- Strong buy3
- Buy4
- Hold0
- Sell0
- Strong sell0
Next earnings
May 9, 2024
Expected May 9, 2024. Consensus EPS estimate -0.77664.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2024 | Sep 1, 2024 | -0.65 | -0.89 | -0.24 | -36.92% |
| May 9, 2024 | Mar 1, 2024 | -0.76 | — | — | — |
| May 9, 2024 | Mar 1, 2024 | -0.76 | -0.77 | -0.01 | -1.32% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 14, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Nov 13, 2024 | Chardan Capital | main | Buy | Buy |
| Nov 13, 2024 | Leerink Partners | main | Outperform | Outperform |
| Oct 31, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 30, 2024 | Chardan Capital | main | Buy | Buy |
| Oct 25, 2024 | Chardan Capital | main | Buy | Buy |
About Lexeo Therapeutics, Inc.
Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- lexeotx.com
News
Lexeo Therapeutics to Present Multiple Oral and Poster Presentations at Key Scientific Conferences in November 
Lexeo Therapeutics Maps Gene Therapy Milestones, Eyes Key 2027 Readout 
Lexeo Therapeutics Eyes NSVT Data as Key Test for LX2020 Gene Therapy 
Lexeo Therapeutics, Inc. (LXEO) Discusses Clinical Assessment and Unmet Need in PKP2 Arrhythmogenic Cardiomyopathy Transcript 
Lexeo Therapeutics to Host Educational Event Focused on Clinical Endpoints and Outcome Measures in PKP2-ACM 
Lexeo Therapeutics to Participate in the Chardan Healthcare Conference 
Lexeo Therapeutics Announces Oral Presentation of LX2006 at the International Congress of Parkinson's Disease and Movement Disorders 2026 (MDS) 
Apertura Gene Therapy to Provide Lexeo Therapeutics Access to TfR1 CapX™ for Program Designed to Treat Friedreich Ataxia 
Lexeo Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum 
Lexeo Therapeutics, Inc. (LXEO) M&A Call Transcript
Your note
Sign in to keep a note on LXEO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ADLER ERIC | Officer | Stock Award(Grant) | Feb 1, 2024 | 26,875 |
| CHOLMONDELEY PAULA H. J. | Director | Purchase | Nov 24, 2024 | 30,627 |
| LONGITUDE CAPITAL PARTNERS IV, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Nov 6, 2023 | 0 |
| LUNDBECKFOND INVEST AS | Beneficial Owner of more than 10% of a Class of Security | Purchase | Nov 6, 2023 | 1,835,960 |
| MCCORMAC PAUL | Chief Technology Officer | Conversion of Exercise of derivative security | Nov 6, 2023 | 17,349 |
| OMEGA FUND VI, L.P | Beneficial Owner of more than 10% of a Class of Security | Purchase | Nov 6, 2023 | 2,157,620 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Janus Henderson Group PLC | 11.38% | 3,763,195 | 23.37M | Sep 29, 2024 |
| Citadel Advisors Llc | 8.24% | 2,723,363 | 16.91M | Sep 29, 2024 |
| Adage Capital Partners GP L.L.C. | 7.86% | 2,597,736 | 16.13M | Sep 29, 2024 |
| D1 Capital Partners, LP | 7.58% | 2,506,607 | 15.57M | Sep 29, 2024 |
| Omega Fund Management, Llc | 7.12% | 2,355,904 | 14.63M | Sep 29, 2024 |
| Eventide Asset Management LLC | 5.61% | 1,855,986 | 11.53M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Mutual Fund Ser Tr-Eventide Healthcare & Life Sciences Fund | 4.61% | 1,525,517 | 9.47M | Sep 29, 2024 |
| Janus Henderson Global Life Sciences Fund | 2.21% | 731,182 | 4.54M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 1.80% | 595,877 | 3.70M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 1.22% | 404,869 | 2.51M | Sep 29, 2024 |
| Vanguard Total Stock Market Index Fund | 0.82% | 272,700 | 1.69M | Sep 29, 2024 |
| iShares Russell 2000 Growth ETF | 0.59% | 194,828 | 1.21M | Oct 30, 2024 |